Background and Aims: Acute severe ulcerative colitis [ASUC] affects one in four patients with UC. Clinical parameters perform modestly in predicting the need for rescue therapy. Sarcopenia and visceral adiposity predict natural history in Crohn's disease, but the role of such metabolic factors on ASUC outcomes is unknown. The aim of this study was to define the effect of sarcopenia and visceral adiposity on outcomes in ASUC. Methods: We studied patients hospitalized for ASUC who underwent an abdominal CT scan during the hospitalization. Quantification of skeletal muscle mass and visceral adiposity was performed by radiologists blinded to the outcome. 
Introduction
Approximately 25% of patients with ulcerative colitis [UC] will develop a severe flare during their lifetime. 1 Episodes of acute severe ulcerative colitis [ASUC] are initially managed with intravenous steroids, but failure occurs in approximately one-third of patients who require medical rescue therapy with infliximab or cyclosporine, or surgical colectomy. [2] [3] [4] [5] However, despite medical rescue, ~20% of patients will still require colectomy. 6 The existing algorithm for management of UC recommends sequential trial of corticosteroids, medical rescue therapy, and surgery. However, this may prolong morbidity in many by delaying initiation of effective medical or surgical treatment. Existing clinical predictors of failure to respond to intravenous steroids, such as C-reactive protein [CRP] and serum albumin, perform inadequately in defining those who may benefit from early medical or surgical rescue therapy. Importantly, they often require evaluation at Day 3-5 of hospitalization, prior to defining therapy failure, thereby prolonging morbidity. Thus, there is an important need for more definitive clinical predictors and/or biomarkers that can be assessed at the time of hospitalization to riskstratify patients with ASUC and identify those who may benefit from upfront rescue therapy.
There is growing recognition of a bidirectional relationship between metabolic factors such as muscle mass, visceral fat, and intestinal inflammation in IBD. Sarcopenia, defined as a loss of skeletal muscle mass and strength, is more common in patients with IBD than in healthy controls. 7, 8 Patients with IBD who have sarcopenia have increased need for surgical resection, and higher risk of postoperative complications and surgical site infections. [9] [10] [11] [12] Sarcopenia has also been demonstrated to be a dynamic marker of UC course, with a higher prevalence in those with increased disease activity, and improvement in muscle mass following medical therapy or colectomy. 8 The prevalence and predictive value of sarcopenia in ASUC has not been previously characterized. We hypothesized that sarcopenia at index hospitalization will be an accurate determinant of severity of inflammation at hospitalization, and a marker of failure to respond to intravenous steroids. Another metabolic factor that has been subject to considerable study is the role of visceral fat. Increased visceral adiposity has been associated with adverse outcomes in CD, including increased disease activity, more aggressive disease behavior, need for surgery, and post-operative endoscopic recurrence. [13] [14] [15] Patients with UC have higher absolute visceral and subcutaneous fat compared with those with CD, but a lower mesenteric fat index [MFI] . 8 Little is known about the impact of visceral adiposity on outcomes in severe UC.
The aims of this study were to [i] determine the association between sarcopenia at admission and failure to respond to intravenous corticosteroid therapy in ASUC; and [ii] examine the association between visceral fat and need for medical rescue therapy or surgery in ASUC.
Methods

Study population
The population for this study consisted of patients hospitalized for ASUC at Massachusetts General Hospital, a tertiary referral center serving the Greater Boston and New England regions. Included were patients with ASUC who were receiving intravenous corticosteroid therapy with either methyl prednisone 60 mg daily or hydrocortisone 300-400 mg daily and who had had an abdominal CT scan performed. Patients with a diagnosis of Crohn's disease or indeterminate colitis, with a prior history of surgical resection, or those who underwent a CT scan following their colectomy were excluded from the study.
Covariates and outcomes
Demographic, clinical, endoscopic, and surgical data were collected via retrospective review of the electronic medical records. Figure 1 ]. 8, 16 Sarcopenic obesity was defined as sarcopenia in the presence of a BMI of ≥30. 17 
Statistical analysis
Continuous variables were reported as means ± standard deviations, or medians ± interquartile ranges, and comparisons were made using the Student's t test or Wilcoxon rank sum test, as appropriate. Categorical variables were reported as absolute numbers, and comparisons were made using the chi-square test or Fishers exact test, as appropriate. We first performed univariate logistic regression to evaluate the relationship between need for any inpatient rescue therapy [medical rescue therapy or colectomy] and each of our predictors of interest. Variables significant in the univariate analysis were included in a multivariable model, in which a two-sided p-value of <0.05 indicated independent statistical significance. Comparison of models was performed with the likelihood ratio test. All analyses were performed using Stata 13.1 [Stata Corp, College Station, Texas]. This study was approved by the institutional review board of Partners HealthCare.
Results
Study cohort
The study cohort included 89 patients. The mean age at hospitalization was 43 years [range 9-86 years], and 36% of the cohort were women. Past treatments for their UC included mesalamines in 87% of the cohort, immunomodulators in 38% of the cohort, and biologics in 33% of the cohort. The mean serum albumin and CRP at admission were 3.4 g/dL and 64 mg/L, respectively. Sixty-eight patients underwent a flexible sigmoidoscopy, and endoscopically severe disease was noted in 59%. The median interval from admission to CT 
Discussion
There is a requirement for more robust predictors of failure of intravenous corticosteroids and of the need for medical or surgical rescue therapy in patients with ASUC, a population at risk for substantial morbidity. Here, we demonstrate sarcopenia to be highly prevalent in patients with ASUC, with as many as 70% of our cohort meeting this radiographic definition. Importantly, sarcopenia was an independent predictor of the need for inpatient medical rescue therapy or colectomy in our ASUC cohort. In contrast, visceral adiposity may play less of a role in ASUC, with neither visceral nor mesenteric adipose fat volume predicting short-or long-term outcomes in ASUC.
Sarcopenia is prevalent in many chronic diseases such as cirrhosis, rheumatoid arthritis, chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease, and it has prognostic implications. The prevalence of sarcopenia was highest [at 48%] in patients with cirrhosis, and was associated with adverse outcomes, including infectious complications and decreased survival. 18 In rheumatoid arthritis, the prevalence of sarcopenia has been estimated to be ~40%, and it has been associated with increased disability. 19, 20 Among those with chronic kidney disease, the prevalence was ~30%, with the highest rates occurring among those with the most severe renal insufficiency. 21 Sarcopenia has been associated with higher rates of major cardiovascular events among patients with chronic kidney disease. 22 Approximately one in four patients with congestive heart failure had sarcopenia, and such patients had an increased likelihood of cardiac events. 23 Finally, the prevalence of sarcopenia in chronic obstructive pulmonary disease is between 15% and 25%, and the presence of sarcopenia has been associated with a decrease in functional status as well as with systemic inflammation, as evidenced by elevated levels of TNFα and IL-6. 24, 25 Only a few prior studies have examined the prevalence and impact of sarcopenia on patients with IBD, however. Zhang et al., in a cohort of ambulatory UC patients, demonstrated that 33.8% of patients with a modified Mayo score of ≥6 had sarcopenia, compared with 4.5% of patients with a score of <6. 8 Our data support this hypothesis, demonstrating that sarcopenia is even more common in ASUC, with over two-thirds [69.5%] of patients meeting the radiologic criteria. The mean L3 SMI in our study cohort was 44 cm 2 /m 2 , which was comparable with previous findings ranging from 40.7 cm 2 /m 2 to 52.22 cm 2 /m 2 in hospitalized or severe disease activity UC cohorts. 8, 9 Possible reasons for the high prevalence of sarcopenia in ASUC include poor nutritional status and/or reduction in protein synthesis in the setting of severe inflammation. 7, 26 The latter theory is supported by van Langenberg et al.'s study evaluating the molecular mechanisms driving lower skeletal muscle mass in patients with CD compared with in controls. In that study, the authors demonstrated a reduction in active, or phosphorylated, Akt, which is involved in muscle synthesis. This suggests that metabolic derangements behind skeletal muscle loss may be related to lack of anabolic activity, rather than increased catabolic activity. Alternatively, while corticosteroids would be expected to increase the risk of sarcopenia, this was previously not found to be the case in a small cohort of IBD patients. 27 In fact, higher cumulative steroid use was associated with lower likelihood of sarcopenia. Sarcopenia has also been shown to be reversible, with treatment directed at underlying disease activity. 28 Subramaniam et al. conducted a prospective study to determine the effect of infliximab on muscle strength and volume in a small cohort of CD patients. Muscle strength and volume were found to significantly increase in the 25 weeks following infliximab initiation. Zhang et al. also demonstrated improvement in sarcopenia following medical therapy in a UC cohort. 8 In the study of Zhang et al., lower rates of sarcopenia were seen following medical therapy in those who had a change in their Mayo score of ≥3. The increasing prevalence of sarcopenia with worsened disease activity, as well as the reversible nature of sarcopenia following IBD therapy, suggests an integrated relationship between luminal inflammation and muscle health. In our study, neither visceral nor subcutaneous adiposity were found to be significant predictors of the need for inpatient rescue in ASUC. Most prior studies examining the association between visceral adiposity and IBD have focused on CD. In a 2015 study, Büning et al. sought to define the relationship between visceral adiposity and clinical course among women with CD. 13 Not only did women with CD have higher absolute levels of visceral fat compared with controls, but visceral adiposity was also associated with more disease activity when analyzed retrospectively and prospectively. A subsequent study with a larger cohort of CD patients demonstrated an association between increased visceral adiposity and adverse outcomes, including risk of penetrating disease and risk of surgery.
14 In addition, a sub-analysis of the POCER study demonstrated a higher risk of post-operative endoscopic recurrence with higher visceral adiposity. 15 This discrepancy regarding the impact of visceral adiposity on clinical outcomes in CD and UC is plausible. A study by Zulian et al. characterized the relationship between bacterial translocation, visceral adiposity, and subtypes of IBD. 29 The authors obtained samples of omental and mesenteric adipose tissue from both UC and CD patients and evaluated gene expression as well as bacterial load. Adipose tissue from UC patients was found to have reduced expression of inflammatory genes when compared with that from CD patients. Furthermore, adipose tissue from UC patients had reduced staining of Enterococcus faecalis compared with adipose tissue from CD patients. As CD is a transmural process and UC is isolated to the mucosa, the former may be associated with more bacterial translocation, and a corresponding increase in inflammatory response and adipocyte proliferation. Therefore, visceral adiposity may not play as important a role in the pathophysiology and corresponding clinical outcomes in UC compared with CD.
There are several strengths of our study. First, to our knowledge, no other study has evaluated sarcopenia in a cohort of ASUC patients. This data expands upon the existing literature of prognostic risk factors in ASUC, with a specific focus on metabolic parameters. Second, most CT scans were performed within the first day of admission, thereby limiting the impact of subsequent course predictors. In addition, the multivariable analysis controlled for potential confounders such as CRP, albumin, and BMI, demonstrating the independently predictive value of sarcopenia on the outcome of interest. Finally, all CT scans were read by radiologists blinded to the clinical outcome, limiting the potential for bias.
There are also several limitations of this study to acknowledge. First, participants in the study population were not defined as patients with ASUC by the Truelove and Witts criteria. However, the study population included hospitalized UC patients requiring intravenous steroids and is, therefore, most likely reflective of those with ASUC. Second, only patients with CT scans performed during their admission were included in the study cohort. Our prior studies demonstrated that 47% of patients with ASUC getting intravenous steroids received inpatient imaging with a CT scan, suggesting generalizability to our findings. 30 It is still possible that CT scans may be preferentially performed on patients presenting with more significant clinical symptoms or laboratory findings, though the fact that all patients had ASUC and received intravenous steroids renders some homogeneity to this cohort. Next, while we utilized previously published criteria to define sarcopenia, there is a variation in the threshold for defining sarcopenia in published studies, and some have relied on a stricter threshold. 9 Finally, some authors have recommended utilizing concurrent information on muscle strength and physical performance, as well as muscle mass, in assigning a diagnosis of sarcopenia. 7 As this was a retrospective study, we did not have access to this information, but this may be examined in future studies.
In conclusion, we demonstrated sarcopenia to be a novel imaging biomarker of the need for escalation of medical therapy or colectomy during an inpatient admission for UC. In contrast, visceral adiposity was not predictive of severity of inflammation or clinical course. There is a need for further study on the bidirectional relationship between metabolic parameters and disease course in IBD in order to elucidate mechanistic implications and to identify modifiable risk factors so as to improve patient outcomes. 
